



## News Release

### **Suven Life Sciences secures 8th Product Patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders**

**HYDERABAD, INDIA (Mar' 29, 2010)** – Suven Life Sciences Ltd (Suven) announces today that the EPO has issued a product Patent:, **EP1919896 to one of their New Chemical Entity (NCE)** which is for the treatment of disorders associated with Neurodegenerative diseases and this **Patent is valid until 2025.**

The granted claims of the patent include the class of **selective 5-HT compounds discovered by Suven** and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

**With this new patent**, Suven has a total of Eight (8) granted European product patents **for their NCEs in CNS therapy**. All the 8 EPO patents have been validated in the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland etc.

**These granted patents are exclusive intellectual property of Suven and are achieved through the internal drug discovery research efforts.** Products out of these inventions may be out-licensed at various phases of pre-clinical and clinical development.

"We are very pleased by the grant of this patent to Suven by European Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated \$20 billion market potential globally" says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. **The Company has twelve (12) internally-discovered therapeutic drug candidates** currently, in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to **developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.**

For more information on Suven/ACT, please visit our Web site at <http://www.suven.com>

#### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;***